• Ana Boned-Ombuena, Jordi Pérez-Panadés, Aurora López-Maside, Maite Miralles-Espí, Sandra Guardiola Vilarroig, Desamparados Adam Ruiz, and Oscar Zurriaga.
• Departamento de Salud Valencia La Fe, Conselleria de Sanitat Universal i Salut Pública de la Comunitat Valenciana, Valencia, España. Electronic address: anaboned@hotmail.com.
• Aten Primaria. 2017 Nov 1; 49 (9): 534548534-548.

ObjectiveTo estimate the prevalence of patients with oral anticoagulant therapy (OAT) in the Region of Valencia and to evaluate the quality of management of OAT with vitaminK antagonists (VKA) carried out in primary healthcare.DesignObservational cross-sectional study conducted through the Health Sentinel Network of the Region of Valencia, which includes a survey and the retrospective analysis of OAT monitoring.SettingPrimary healthcare, Region of Valencia, Spain.SubjectsAll patients aged 18years or older on OAT who consulted during the year 2014. The population covered by the 59 doctors of the Health Sentinel Network constitutes 2.2% of the adult population of the Region of Valencia, and it is representative of it.Key MeasurementsDemographic, socioeconomic and health data as well as information concerning OAT. Quality of OAT management with VKA was assessed by means of the percentage of time in therapeutic range (TTR), computed using the Rosendaal method.ResultsA total of 1,144 patients were recorded (mean age 74.5±11 years; 49.7% women). Prevalence of OAT in the Region of Valencia is 1.3 cases per 100 population. The characteristic profile of these patients is an old person, with several comorbidities and a low level of education, who lives accompanied. Atrial fibrillation is the most common indication. 82.8% of patients on OAT with VKA were monitored in primary healthcare. The average TTR was 65.0%, and 53.9% of patients had a TTR ≥65%. Among inadequately controlled patients, 74.4% were perceived as well-controlled by their primary care doctor.ConclusionsPrevalence of OAT is high, and it is expected to increase. The degree of control achieved meets the generally accepted quality standard (mean TTR ≥65%), and it is comparable to that observed in other national and international studies. However, there is wide scope for improvement. It is crucial to optimize the management of this therapy in the most effective and cost-effective way. Among other measures, access of physicians to their patients' clinical information should be improved.Copyright © 2017 Elsevier España, S.L.U. All rights reserved.

29 keywords...

hide…